Spots Global Cancer Trial Database for chronic myelomonocytic leukemia (cmml)
Every month we try and update this database with for chronic myelomonocytic leukemia (cmml) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations | NCT04409639 | Chronic Myelomo... | Cobimetinib | 18 Years - | University of Utah | |
| Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia | NCT00528983 | Myelodysplastic... Chronic Myelomo... Acute Myelogeno... | Subcutaneous (S... Oral Azacitidin... Oral Azacitidin... | 18 Years - | Celgene | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma | NCT00761722 | Acute Myeloid L... Myelodysplastic... Lymphoma Multiple Myelom... Leukemia, Myelo... | azacitidine | 18 Years - | Celgene | |
| Pharmacokinetics, Tolerability and Safety of NEX-18a | NCT05048498 | Myelodysplastic... Chronic Myelomo... Acute Myeloid L... | NEX-18a injecti... Azacitidine Inj... | 18 Years - | Nanexa AB | |
| Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) | NCT01736683 | Anemia Myelodysplastic... Chronic Myelomo... Low to Intermed... Myelodysplastic... Chronic Myelomo... | Sotatercept | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | NCT01842646 | Myelodysplastic... Chronic Myelomo... | PF-04449913 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | NCT00664677 | Leukemias Acute Myeloid L... Acute Lymphocyt... Adult T Cell Le... Chronic Myeloid... Chronic Lymphoc... Myelodysplastic... Chronic Myelomo... | Terameprocol (E... | 18 Years - | Erimos Pharmaceuticals | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients | NCT01613976 | Myelodysplastic... Chronic Myelomo... Acute Myeloid L... | Panobinostat | 20 Years - | Novartis | |
| Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | NCT01629082 | Myeldysplastic ... Chronic Myelomo... Bone Marrow Dis... Neutropenia Acute Myeloid L... | Clofarabine Lenalidomide | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations | NCT04409639 | Chronic Myelomo... | Cobimetinib | 18 Years - | University of Utah | |
| Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma | NCT00761722 | Acute Myeloid L... Myelodysplastic... Lymphoma Multiple Myelom... Leukemia, Myelo... | azacitidine | 18 Years - | Celgene | |
| Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL | NCT02147873 | Myelodysplastic... Chronic Myelomo... | birinapant Azacitidine Placebo | 18 Years - | TetraLogic Pharmaceuticals | |
| Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | NCT01842646 | Myelodysplastic... Chronic Myelomo... | PF-04449913 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| SNS-301 Monotherapy in High Risk MDS and CMML | NCT04217720 | Myelodysplastic... Chronic Myelomo... | SNS-301 | 18 Years - | Sensei Biotherapeutics, Inc. | |
| Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma | NCT00761722 | Acute Myeloid L... Myelodysplastic... Lymphoma Multiple Myelom... Leukemia, Myelo... | azacitidine | 18 Years - | Celgene | |
| Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations | NCT04409639 | Chronic Myelomo... | Cobimetinib | 18 Years - | University of Utah | |
| Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | NCT03922100 | Acute Myeloid L... Chronic Myelomo... | NMS-03592088 | 18 Years - | Nerviano Medical Sciences | |
| Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | NCT01842646 | Myelodysplastic... Chronic Myelomo... | PF-04449913 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
